AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21570146 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring with a blood glucose meter (Group B)
Number of subjects: 108
Study 21570146 — intervention group
Group type: COMPARATOR
Intervention: Control group without self-monitoring (Group C)
Number of subjects: 108
Study 19714376 — intervention group
Group type: EXPERIMENTAL
Intervention: SARME with pterygomaxillary disjunction (SARME+PP)
Number of subjects: 50
Study 19714376 — intervention group
Group type: COMPARATOR
Intervention: SARME without pterygomaxillary disjunction (SARME-PP)
Number of subjects: 50
Study 16897144 — intervention group
Group type: EXPERIMENTAL
Intervention: Music stimulation during the procedure
Number of subjects: 83
Study 16897144 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapeutic coaching
Number of subjects: 83
Study 16897144 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 83
Study 15505001 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 95
Study 15505001 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 95
Study 11529360 — intervention group
Group type: EXPERIMENTAL
Intervention: Contaminated endometriotic contents during oocyte retrieval
Number of subjects: 38
Study 11529360 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contaminated endometriotic contents during oocyte retrieval
Number of subjects: 38
Study 11529360 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study 9754167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy for ROP (Group A)
Number of subjects: 1465
Study 9754167 — intervention group
Group type: COMPARATOR
Intervention: Natural history (Group B)
Number of subjects: 1465
Study 7918139 — intervention group
Group type: EXPERIMENTAL
Intervention: Simendan 1.0 mg
Number of subjects: 8
Study 7918139 — intervention group
Group type: EXPERIMENTAL
Intervention: Simendan 2.0 mg
Number of subjects: 8
Study 7918139 — intervention group
Group type: EXPERIMENTAL
Intervention: Simendan 5.0 mg
Number of subjects: 8
Study 7918139 — intervention group
Group type: EXPERIMENTAL
Intervention: Simendan 10.0 mg
Number of subjects: 8
Study 3451888 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg falipamil
Number of subjects: 0
Study 3451888 — intervention group
Group type: COMPARATOR
Intervention: Low doses of atropine
Number of subjects: 0
Study 3451888 — intervention group
Group type: COMPARATOR
Intervention: 1 mg cumulative dose of atropine
Number of subjects: 0
Study 3451888 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg falipamil
Number of subjects: 0
Study 3451888 — intervention group
Group type: EXPERIMENTAL
Intervention: ULFS 49 Cl (3 different oral doses)
Number of subjects: 0
Study 3451888 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 2.5 mg p.o. (minimal effective dose)
Number of subjects: 0
Study 3451888 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 5 mg p.o. (therapeutic dose)
Number of subjects: 0
Study 3451888 — intervention group
Group type: EXPERIMENTAL
Intervention: falipamil
Number of subjects: 0
Study 3451888 — intervention group
Group type: EXPERIMENTAL
Intervention: ULFS 49 Cl
Number of subjects: 0
Study 3451888 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-effects typical for 'specific bradycardic agents'
Number of subjects: 0
Study 29374674 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention providing information, motivation, and support for medication adherence, smoking cessation, healthy diet, and exercise.
Number of subjects: 1400
Study 29374674 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention
Number of subjects: 1400
Study 28376651 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 67
Study 28376651 — intervention group
Group type: EXPERIMENTAL
Intervention: brinzolamide 1.0%/timolol maleate 0.5% fixed combination (BTFC)
Number of subjects: 67
Study 28376651 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy eyes)
Number of subjects: 67
Study 26252845 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent insertion
Number of subjects: 52
Study 26252845 — intervention group
Group type: COMPARATOR
Intervention: Surgical decompression
Number of subjects: 52
Study 23232154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg, max 600 mg) and Codeine (1 mg/kg, max 60 mg)
Number of subjects: 81
Study 23232154 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (10 mg/kg, max 600 mg) and Placebo
Number of subjects: 81
Study 21645639 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 40
Study 21645639 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 20108849 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week neuromuscular-training program including plyometric, functional-strengthening, balance, and stability-ball exercises
Number of subjects: 62
Study 20108849 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week neuromuscular-training program
Number of subjects: 62
Study 17046324 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine loading
Number of subjects: 8
Study 17046324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12772727 — intervention group
Group type: EXPERIMENTAL
Intervention: BCR of 7.9 mm
Number of subjects: 114
Study 12772727 — intervention group
Group type: EXPERIMENTAL
Intervention: BCR of 8.3 mm
Number of subjects: 114
Study 12772727 — intervention group
Group type: EXPERIMENTAL
Intervention: BCR of 8.7 mm
Number of subjects: 114
Study 12772727 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian eyes
Number of subjects: 114
Study 12772727 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Asian eyes with steep BCR
Number of subjects: 114
Study 10702174 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Zn/d
Number of subjects: 219
Study 10702174 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Fe/d
Number of subjects: 219
Study 10702174 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Zn/d plus 20 mg Fe/d
Number of subjects: 219
Study 10702174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 9316954 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 31
Study 9316954 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 31
Study 8404191 — intervention group
Group type: COMPARATOR
Intervention: SHRZ/HR regimen (2 months of daily streptomycin, isoniazid, rifampin, and pyrazinamide followed by 4 months of isoniazid plus rifampin)
Number of subjects: 35
Study 8404191 — intervention group
Group type: EXPERIMENTAL
Intervention: SHZ Cipro/H Cipro regimen (2 months of daily streptomycin, isoniazid, pyrazinamide, and ciprofloxacin followed by 4 months of isoniazid plus ciprofloxacin)
Number of subjects: 35
Study 3435909 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 301
Study 3435909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 28222574 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (E: cycle ergometer 45 min, 50% VO2peak)
Number of subjects: 13
Study 28222574 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise (E: cycle ergometer 45 min, 50% VO2peak)
Number of subjects: 13
Study 27793237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil in combination with low-dose hyperbaric bupivacaine
Number of subjects: 0
Study 27793237 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24823692 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse's functional limitations
Number of subjects: 6
Study 24823692 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal resources
Number of subjects: 6
Study 22162570 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional fluorouracil, leucovorin, and oxaliplatin
Number of subjects: 364
Study 22162570 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan, leucovorin, and fluorouracil
Number of subjects: 364
Study 22162570 — intervention group
Group type: EXPERIMENTAL
Intervention: pcCRC
Number of subjects: 364
Study 20423964 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary HPV DNA test (hybrid capture II) with cytology triage if the result was positive
Number of subjects: 58076
Study 20423964 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytological screening (reference)
Number of subjects: 58076
Study 20423964 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV arm
Number of subjects: 58076
Study 20423964 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal or negative test result in HPV arm
Number of subjects: 58076
Study 17898705 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir with omeprazole simultaneously
Number of subjects: 12
Study 17898705 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir with omeprazole 2 h apart
Number of subjects: 12
Study 17898705 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir/ritonavir without omeprazole
Number of subjects: 12
Study 16860169 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 325 mg/d for 1 week, followed by ASA 100 mg/d plus clopidogrel 300 mg loading dose followed by 100 mg/d for 36 weeks (ASA+Clop group)
Number of subjects: 86
Study 16860169 — intervention group
Group type: COMPARATOR
Intervention: ASA alone (325 mg/d for 1 week, followed by 75 mg/d for 36 weeks) (ASA group)
Number of subjects: 86
Study 12623974 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day, given 8 hours after awakening (time 2)
Number of subjects: 341
Study 12623974 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day, given before bedtime (time 3)
Number of subjects: 341
Study 12623974 — intervention group
Group type: COMPARATOR
Intervention: Placebo given at bedtime
Number of subjects: 341
Study 10840491 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic external defibrillators (AEDs)
Number of subjects: 6
Study 10840491 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6
Study 9337682 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 79
Study 8408538 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling intervention (three sessions of counselling before, during, and after the first treatment cycle)
Number of subjects: 0
Study 8408538 — intervention group
Group type: COMPARATOR
Intervention: Control group (information about the treatment programme only)
Number of subjects: 0
Study 3547370 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral bupivacaine
Number of subjects: 26
Study 3547370 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (Control)
Number of subjects: 26
Study 31219517 — intervention group
Group type: EXPERIMENTAL
Intervention: mECX+L (modified ECX plus lapatinib)
Number of subjects: 46
Study 31219517 — intervention group
Group type: COMPARATOR
Intervention: sECX (standard ECX)
Number of subjects: 46
Study 28968877 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based and village-wide preventive chemotherapy strategies (MDA) for Schistosoma mansoni
Number of subjects: 0
Study 28968877 — intervention group
Group type: COMPARATOR
Intervention: Mass drug administration (MDA)
Number of subjects: 0
Study 28968877 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA strategies
Number of subjects: 0
Study 28968877 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive analysis from prior year data
Number of subjects: 0
Study 25148380 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 79
Study 23405376 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered testing using the Gen-Probe APTIMA Combo 2 (AC2) kit
Number of subjects: 374
Study 21884958 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation (RD)
Number of subjects: 46
Study 21884958 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 46
Study 19706084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% clindamycin and 0.025% tretinoin (CLIN/RA) gel
Number of subjects: 1710
Study 19706084 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 1710
Study 19706084 — intervention group
Group type: COMPARATOR
Intervention: 1.2% clindamycin (CLIN)
Number of subjects: 1710
Study 19706084 — intervention group
Group type: COMPARATOR
Intervention: 0.025% tretinoin (RA)
Number of subjects: 1710
Study 16730066 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐mg intralesional injection of 5‐FU weekly for 2 weeks
Number of subjects: 109
Study 16730066 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐mg intralesional injection of triamcinolone
Number of subjects: 109
Study 16730066 — intervention group
Group type: COMPARATOR
Intervention: Control group (topical steroid alone)
Number of subjects: 109
Study 15249533 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE programme
Number of subjects: 29
Study 15249533 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE training and intervention materials
Number of subjects: 29
Study 15249533 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling implementation
Number of subjects: 29
Study 11744967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide 5 mg/ml injection
Number of subjects: 26
Study 11744967 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple incision and curettage
Number of subjects: 26
Study 11744967 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision, curettage and intralesional triamcinolone acetonide injection
Number of subjects: 26
Study 9269010 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg sublingual triazolam
Number of subjects: 0
Study 9269010 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg oral triazolam
Number of subjects: 0
Study 9269010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8329825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GHRH(1-29)-NH2 at 0.25 microgram/kg
Number of subjects: 30
Study 8329825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GHRH(1-29)-NH2 at 1-2 micrograms/kg
Number of subjects: 30
Study 8329825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal GHRH(1-29)-NH2 at 50 micrograms/kg
Number of subjects: 30
Study 8329825 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intranasal GHRH(1-29)-NH2 administration
Number of subjects: 30
Study 3526610 — intervention group
Group type: EXPERIMENTAL
Intervention: NG suction (Group I)
Number of subjects: 60
Study 30612537 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based selection for EVT
Number of subjects: 1265
Study 30612537 — intervention group
Group type: COMPARATOR
Intervention: CTA-based selection for EVT
Number of subjects: 1265
Study 27779907 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 25265874 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely transmitted touch
Number of subjects: 0
Study 22692119 — intervention group
Group type: EXPERIMENTAL
Intervention: o‐uchi‐gari protocol
Number of subjects: 10
Study 22692119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen consumption
Number of subjects: 10
Study 22692119 — intervention group
Group type: EXPERIMENTAL
Intervention: total energy expenditure per repetition
Number of subjects: 10
Study 22692119 — intervention group
Group type: EXPERIMENTAL
Intervention: training protocols
Number of subjects: 10
Study 21742946 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soy diet (2 servings of soy milk, tofu, or soy nuts, ∼50 mg of isoflavones per day)
Number of subjects: 96
Study 21742946 — intervention group
Group type: COMPARATOR
Intervention: Low-soy diet (usual diet)
Number of subjects: 96
Study 21742946 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soy diet
Number of subjects: 96
Study 19356389 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily (Days 1 and 15) + Erythromycin 500 mg three times daily (Days 9 - 21)
Number of subjects: 16
Study 16485755 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet coherence
Number of subjects: 26
Study 16485755 — intervention group
Group type: COMPARATOR
Intervention: Fourier coherence
Number of subjects: 26
Study 12956481 — intervention group
Group type: EXPERIMENTAL
Intervention: Biostite
Number of subjects: 96
Study 12956481 — intervention group
Group type: COMPARATOR
Intervention: No defect fill (Control)
Number of subjects: 96
Study 10903014 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular NSAIDs
Number of subjects: 844
Study 10903014 — intervention group
Group type: COMPARATOR
Intervention: IVRA NSAIDs
Number of subjects: 844
Study 10903014 — intervention group
Group type: COMPARATOR
Intervention: Intrawound NSAIDs
Number of subjects: 844
Study 10903014 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration with NSAIDs
Number of subjects: 844
Study 8955540 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwab‐Gilleard Depression Scale (SGDS)
Number of subjects: 166
Study 8955540 — intervention group
Group type: COMPARATOR
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 166
Study 8955540 — intervention group
Group type: COMPARATOR
Intervention: Short‐Comprehensive Assessment and Referral Evaluation (CARE)
Number of subjects: 166
Study 8955540 — intervention group
Group type: COMPARATOR
Intervention: Clifton Assessment Procedures for the Elderly (CAPE)
Number of subjects: 166
Study 8955540 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwab‐Gilleard Depression Scale (SGDS) and CARE (14 months previously)
Number of subjects: 166
Study 1519573 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg/day for 4 weeks)
Number of subjects: 13
Study 1519573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 4 weeks)
Number of subjects: 13
Study 6470191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment in 21 children
Number of subjects: 61
Study 30819485 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 30
Study 30819485 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 30
Study 30819485 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TRA and TFA
Number of subjects: 30
Study 29710676 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + MP group
Number of subjects: 115
Study 29710676 — intervention group
Group type: COMPARATOR
Intervention: PRP group
Number of subjects: 115
Study 29710676 — intervention group
Group type: COMPARATOR
Intervention: MP group
Number of subjects: 115
Study 25969346 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compressions after a night shift
Number of subjects: 67
Study 25969346 — intervention group
Group type: COMPARATOR
Intervention: Control day chest compressions
Number of subjects: 67
Study 24262813 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg D-cycloserine administered after each of ten CBT sessions
Number of subjects: 27
Study 24262813 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered after each of ten CBT sessions
Number of subjects: 27
Study 22724029 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin (PM) 20 mg/kg/day for 21 days
Number of subjects: 205
Study 22724029 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate (SSG) 20 mg/kg/day for 30 days
Number of subjects: 205
Study 22724029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PM (15 mg/kg/day) and SSG (20 mg/kg/day) for 17 days
Number of subjects: 205
Study 22724029 — intervention group
Group type: EXPERIMENTAL
Intervention: End of treatment efficacy for PM
Number of subjects: 205
Study 22724029 — intervention group
Group type: EXPERIMENTAL
Intervention: End of treatment efficacy for SSG & PM
Number of subjects: 205
Study 20471234 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (BDP)
Number of subjects: 15
Study 20471234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of BDP plus montelukast (ML)
Number of subjects: 15
Study 20471234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18605812 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 1275
Study 18605812 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 1275
Study 16260434 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving Cancer Competently Intervention Program‐Newly Diagnosed (SCCIP‐ND)
Number of subjects: 19
Study 16260434 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 19
Study 12499890 — intervention group
Group type: EXPERIMENTAL
Intervention: ELAD therapy
Number of subjects: 5
Study 10567271 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless aortic valve (SAV)
Number of subjects: 180
Study 10567271 — intervention group
Group type: COMPARATOR
Intervention: Conventional stented bioprosthesis (CSB)
Number of subjects: 180
Study 8915668 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin 8 mg/m2/day for 5 days
Number of subjects: 786
Study 8915668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubidazone 200 mg/m2/day for 4 days
Number of subjects: 786
Study 8915668 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ARA-C plus m-Amsa
Number of subjects: 786
Study 8915668 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 786
Study 8915668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive consolidation chemotherapy (ICC)
Number of subjects: 786
Study 8915668 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous unpurged bone marrow transplantation (ABMT)
Number of subjects: 786
Study 8915668 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF 5 micrograms/kg/day
Number of subjects: 786
Study 8915668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 786
Study 8915668 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 786
Study 1670621 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline treatment for 3 months
Number of subjects: 0
Study 1670621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6882615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid preparation (Diazemuls)
Number of subjects: 100